Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
View: Text | PDF
Research Article Infectious disease Inflammation

EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages

  • Text
  • PDF
Abstract

Alveolar macrophages (AMs) act as gatekeepers of the lung’s immune responses, serving essential roles in recognizing and eliminating pathogens. The transcription factor (TF) early growth response 2 (EGR2) has been recently described as required for mature AMs in mice; however, its mechanisms of action have not been explored. Here, we identified EGR2 as an epigenomic regulator and likely direct proximal transcriptional activator in AMs using epigenomic approaches (RNA sequencing, ATAC sequencing, and CUT&RUN). The predicted direct proximal targets of EGR2 included a subset of AM identity genes and ones related to pathogen recognition, phagosome maturation, and adhesion, such as Clec7a, Atp6v0d2, Itgb2, Rhoc, and Tmsb10. We provided evidence that EGR2 deficiency led to impaired zymosan internalization and reduced the capacity to respond to Aspergillus fumigatus. Mechanistically, the lack of EGR2 altered the transcriptional response, secreted cytokines (i.e., CXCL11), and inflammation-resolving lipid mediators (i.e., RvE1) of AMs during in vivo zymosan-induced inflammation, which manifested in impaired resolution. Our findings demonstrated that EGR2 is a key proximal transcriptional activator and epigenomic bookmark in AMs responsible for select, distinct components of cell identity and a protective transcriptional and epigenomic program against fungi.

Authors

Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy

×

Figure 9

Impaired clearance of AF in myeloid EGR2-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
Impaired clearance of AF in myeloid EGR2-deficient mice.
(A and D) Overv...
(A and D) Overview of the experimental setup to define the elimination efficiency of Egr2+/+ and Egr2fl/fl AMs ex vivo by colony formation assay (A) and time-lapse microscopy (D). (B) The bar graphs represent the (mean ± SEM) values of AF colonies after 1 hour and 7 hours of cotreatment with Egr2+/+ (n1hr = 6, n3hrs = 9) and Egr2fl/fl (n1hr = 6, n3hrs = 9) AMs. (C) The percentage of eliminated AF conidia based on the mean colony-forming capacity after uptake and elimination period in Egr2+/+ and Egr2fl/fl AMs. (E) Representative images of time-lapse microscopy after washing the AF conidia from Egr2+/+ and Egr2fl/fl AM coculture and at 8 and 11 hours (blue arrows: hypha-containing AMs). (F) The (mean ± SEM) value of hypha-containing AMs after 11 hours in Egr2+/+ and Egr2fl/fl cells measured using time-lapse microscopic images (bar plot). (G) The (mean ± SEM) value of the start point of hypha growth in Egr2+/+ (n = 14) and Egr2fl/fl (n = 14) AMs based on time-lapse microscopic images. (H) The schematic summary of in vivo AF infection model. (I) The (mean ± SEM) value of the percentage of hypha-containing Egr2+/+ and Egr2fl/fl AMs after 24-hour AF infection based on time-lapse microscopic images (bar plot). (J) The bar plots represent the (mean ± SEM) values of AF colonies after 1- and 2-day AF infection in Egr2+/+ (nday1 = 5, nday2 = 9) and Egr2fl/fl (nday1 = 6, nday2 = 6) lungs. (K) The change in body mass in Egr2+/+ (n = 6) and Egr2fl/fl (n = 9) mice after AF infection normalized to the untreated mean total body mass. (L) Representative images of paraffin-embedded, H&E-stained and Masson’s trichrome–stained Egr2+/+ and Egr2fl/fl lungs after 5-day AF infection (arrows: fibrotic area). (M) The percentage (mean ± SEM) of fibrotic area in inflamed fields based on Masson’s trichrome–stained lungs of Egr2+/+ (n = 9) and Egr2fl/fl (n = 11) mice after 5-day AF infection (t test, *P ≤ 0.05, ****P ≤ 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts